Boston Scientific has completed the first post-FDA approval cases in the U.S. with its Farapulse pulsed field ablation system. In a LinkedIn post, Nick Spadea-Anello, president, Electrophysiology, Boston Scientific, announced the first commercial use for the AFib treatment. Marlborough, Massachusetts-based Boston Scientific won the approval for Farapulse last month. In doing so, it became second […]
Boston Scientific
Layoffs in medtech: These companies recently reduced their workforce
The workforce reduction trend has swept the economy recently, and unfortunately, the medtech space is not immune to layoffs. You’ve probably read about the ongoing layoffs sweeping the tech industry, media and more. For instance, Yahoo, Disney, Zoom and more all reported workforce reductions as companies across industries grapple with economic pressures. Think inflation, supply […]
FDA expands approval for Boston Scientific spinal cord stim to include chronic back pain without prior back surgery
Boston Scientific announced today that the FDA approved an expanded indication for its WaveWriter spinal cord stimulation (SCS) systems. The indication covers chronic low back and leg pain in people without prior back surgery — called non-surgical back pain (NSBP). Boston Scientific says first-line treatment for people with chronic back pain tends to have limitations. […]
What’s next for Boston Scientific after Farapulse’s FDA approval?
Chief Medical Officer Dr. Ken Stein explains the plans at Boston Scientific after its landmark pulsed field ablation approval. On Jan. 31, Boston Scientific became the second company to receive FDA approval for a pulsed field ablation (PFA) system that treats AFib. The landmark approval came just over a month after Medtronic became the first […]
Boston Scientific picks new investor relations VP, chief accounting officer
Boston Scientific announced that it appointed a new SVP of investor relations and a new chief accounting officer. In an SEC filing, the company announced the appointments, made on Jan. 26. Jonathan Monson takes over as SVP, investor relations, effective March 1, 2024. Monson currently serves as SVP, global controller and chief accounting officer, positions […]
FDA approves Farapulse pulsed field ablation tech from Boston Scientific
Boston Scientific announced today that it received FDA approval for its Farapulse pulsed field ablation (PFA) system. Shares of BSX were up more than 2% at $62.79 in morning trading on the back of the news, as the company also posted strong fourth-quarter earnings results. MassDevice‘s MedTech 100 Index was up nearly 1%. The much-anticipated […]
Boston Scientific launches VersaVue single-use flexible cystoscope
Boston Scientific announced today that it began a limited market release of its VersaVue single-use flexible cystoscope. VersaVue expands the company’s product offerings intended to help clinicians diagnose and treat urinary tract conditions. The scope, which received FDA clearance in October, provides visualization of the lining of the bladder and urethra. It displays images to […]
Former Boston Scientific exec joins pulsed field ablation company Mirai Medical’s board
Mirai Medical announced today that it appointed former Boston Scientific executive David A. Pierce as a non-executive board director. Pierce spent 31 years at Boston Scientific, gaining valuable experience in product commercialization, market access and clinical change management. Much of his work came in the gastrointestinal endoscopy space, providing expertise he can now bring to […]
Boston Scientific has positive spinal cord stimulation data
Boston Scientific announced positive one-year results from a trial evaluating its spinal cord stimulation (SCS) technology. The SOLIS randomized control trial demonstrated sustained pain relief with the WaveWriter Alpha SCS system for treating non-surgical back pain (NSBP). Boston Scientific presented data at the 2024 North American Neuromodulation Society (NANS) meeting in Las Vegas. Dr. James […]
Boston Scientific to acquire Axonics for $3.7B
Boston Scientific announced today that it agreed to acquire Axonics (Nasdaq:AXNX) in a deal worth approximately $3.7 billion. Shares of AXNX skyrocketed before the market opened today, rising 21.1% to $69.72 apiece. Shares of BSX stayed even. Marlborough, Massachusetts-based Boston Scientific priced the acquisition at $71 in cash per share. It amounts to an equity […]
Boston Scientific initiates new Farapulse trial, expects FDA approval in 2024
Boston Scientific announced today that it initiated the AVANT GUARD clinical trial to evaluate its Farapulse pulsed field ablation (PFA) system. The company also says it now anticipates FDA approval for Farapulse in the first quarter of 2024. AVANT GUARD looks at the safety and effectiveness of Farapulse as a first-line treatment for persistent AFib. […]